

Gibson Dunn Advises Coastlands Capital on up to \$40 Million Financing for AN2 Therapeutics, Inc.

Firm News | March 9, 2026

Gibson Dunn represented Coastlands Capital as lead investor in the up to \$40 million private placement financing for AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform.

Gibson Dunn regularly advises life sciences investors on private placement financings for clinical-stage biopharmaceutical companies.

The Gibson Dunn team included Ryan Murr and Branden Berns.

Related People

[Ryan A. Murr](#)

[Branden C. Berns](#)

Related Capabilities

[Life Sciences](#)

[Finance](#)

[Private Equity](#)

[Emerging Companies / Venture Capital](#)